CION Ameerpet
Some things genuinely reduce ovarian cancer risk, and most of what circulates online does not. The measures with real evidence behind them are mostly reproductive — and one of them is a decision many women make anyway, for other reasons.
Look at the list of measures that genuinely reduce ovarian cancer risk — combined hormonal contraception, pregnancy, breastfeeding, tubal surgery — and something becomes obvious. They are almost all reproductive, and most of them share one feature: they interrupt ovulation.
The long-standing explanation is that each ovulation involves a small rupture of the ovarian surface followed by repair, and that repeated cycles of damage and repair across a reproductive lifetime create opportunities for something to go wrong. Anything that reduces the total number of ovulations therefore reduces that cumulative exposure. It also explains the risk factors that mirror the protective ones — early menarche, late menopause and never having been pregnant all mean more ovulations.
That model is not the whole story, and the fallopian tube origin of much high-grade serous cancer complicates it. But it holds up well enough to explain the pattern, and it usefully predicts why tubal surgery also protects — which the ovulation model alone would not have anticipated. The practical point is that the effective measures are specific and identifiable, not a matter of general healthy living.
Contraception, pregnancy and breastfeeding all interrupt ovulation, and all reduce risk measurably.
Early menarche, late menopause and never having been pregnant all mean more ovulations across a lifetime.
Tubal surgery also protects, which points to the fallopian tube origin of much high-grade serous disease.
Because much high-grade serous ovarian cancer appears to begin in the fallopian tube, surgeons increasingly offer opportunistic salpingectomy — removing the tubes rather than simply tying them — when a woman is having a hysterectomy or requesting permanent contraception and has completed her family. The ovaries are left in place, so there is no surgical menopause and no hormonal consequence. It adds little to an operation already being performed. If you are having pelvic surgery and your family is complete, this is worth asking about explicitly, because it is not always offered. Source: NCCN Ovarian Cancer guidelines; published data on tubal ligation and salpingectomy.
Roughly in order of how much evidence supports each, and how much difference each makes.
The best-evidenced non-surgical measure by a clear margin. Combined oral contraception substantially reduces ovarian cancer risk, the effect increases with duration of use, and — importantly — it persists for many years after stopping. The reduction has been observed in BRCA carriers as well as in the general population.
It is not a free intervention and should not be presented as one. Combined contraception carries its own considerations including a small effect on breast cancer risk, which matters particularly for BRCA carriers, and it is not suitable for everyone. It is a genuine trade-off worth discussing with a doctor rather than a supplement to take.
Having been pregnant reduces ovarian cancer risk, and the effect increases with the number of pregnancies. Breastfeeding reduces it further, again with duration. Both suppress ovulation for extended periods, which fits the underlying model well.
Nobody sensibly plans a pregnancy for cancer prevention, and this is included for accuracy rather than as advice. Its practical relevance is that it explains why never having been pregnant appears as a risk factor — which is context rather than a reason for regret, since the absolute risk remains low either way.
Having the fallopian tubes tied is associated with a meaningful reduction in ovarian cancer risk. Complete removal of the tubes — salpingectomy — appears to reduce it further, which makes sense given that much high-grade serous cancer seems to originate in the tube.
This is the measure most worth acting on, because it is available at no additional cost or risk to a woman already having pelvic surgery. If you are having a hysterectomy or requesting permanent contraception and your family is complete, ask whether the tubes can be removed rather than tied. The ovaries stay, so there is no menopause consequence.
By far the most effective measure available, lowering ovarian cancer risk by around eighty per cent. It is not, however, a general prevention strategy — it is reserved for women at confirmed high hereditary risk, because it causes immediate surgical menopause with real long-term consequences for bone and cardiovascular health.
For a BRCA1 or BRCA2 carrier, or a woman with Lynch syndrome or another high-risk variant, it is the central intervention. For a woman at population risk it would do considerably more harm than good. See risk-reducing surgery.
Not a risk-reducing measure in itself, but the step that determines whether the effective interventions apply to you at all. A woman who does not know that ovarian and breast cancer run down her father's side is not in a position to access anything on this list beyond the general measures.
Building a proper three-generation family history from both sides costs nothing and takes an evening. Where it meets recognised criteria, genetic counselling follows — and CION delivers that in-house. See family history.
Not smoking reduces the risk of one less common ovarian subtype, mucinous carcinoma, and reduces a great many other risks besides. Maintaining a healthy weight is associated with lower risk of several cancers including endometrial cancer, where the association is much stronger than for ovarian.
These are worth doing on their own merits and they are not nothing. But they should be described honestly: their effect on ovarian cancer risk specifically is modest compared with the reproductive factors above, and presenting them as ovarian cancer prevention overstates what they achieve.
This half matters as much as the other. A great deal of confident advice circulates with nothing behind it.
No dietary supplement, superfood, cleanse or detox regimen has been shown to reduce ovarian cancer risk. Some supplements interact with medications and a few carry their own risks at high doses. A generally good diet is worth having for many reasons; it is not an ovarian cancer prevention strategy, and anything sold as one is being sold rather than evidenced.
This is the most consequential misunderstanding on the page. CA-125 and transvaginal ultrasound have not been shown to reduce ovarian cancer deaths, even in high-risk women, and screening does not prevent anything in any case — at best it detects. Believing you are protected because you have annual tests is worse than knowing you are not. See high-risk surveillance.
None of these measures eliminates risk. Report these symptoms whatever you have or have not done.
New within the past year and present on more than 12 days a month. See persistent bloating.
Early satiety — unable to finish meals you managed easily six months ago.
A dull persistent ache present most days. Persistence matters considerably more than severity.
Needing to pass urine more often or urgently, with urine tests that come back clear.
Losing weight without trying always warrants assessment, whatever your risk profile.
Any bleeding after menopause warrants prompt assessment in its own right.
Even risk-reducing surgery leaves a small residual peritoneal risk. Symptom awareness remains worthwhile no matter what else you have done.
The measures that genuinely work involve real trade-offs — contraception has its own risk profile, and surgery is only for confirmed high risk. That is a conversation, not a checklist.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. Genetic counselling is in-house at CION if your family history warrants assessment.
Prevention advice for ovarian cancer is unusually poor online, and the reason is structural: the measures that genuinely work are mostly reproductive decisions with real trade-offs, which does not make for a satisfying list of things to do. So the vacuum fills with diets and supplements, which are easy to recommend and do nothing.
Your first consultation at CION is free and runs to about 45 minutes. The most useful conversation is usually not a list at all — it is establishing where you actually sit. A woman at population risk with no family history is in a completely different position from a BRCA1 carrier, and almost everything on this page applies differently to each.
Where a family history warrants it, genetic counselling and BRCA and HRD testing are delivered in-house at CION. Where cancer does develop, chemotherapy and maintenance therapy are delivered in-house across 35+ centres in Telangana and Andhra Pradesh. Risk-reducing and gynaecologic-oncology surgery is coordinated with specialist partner centres and may be billed there — we state that upfront.
Free and unhurried. Long enough to establish where you actually sit before discussing what applies to you.
If you are having pelvic surgery and your family is complete, removing the tubes rather than tying them is worth requesting.
Where a family history warrants assessment, counselling and testing happen here rather than across referrals.
No supplement or cleanse reduces ovarian cancer risk, and screening is not prevention. We would rather be plain about it.
A rough guide to the strength of evidence and who each measure actually applies to.
| Measure | Evidence | Who it applies to |
|---|---|---|
| Risk-reducing salpingo-oophorectomy | Strong — around 80% risk reduction. | Confirmed high hereditary risk only. Not a general measure. |
| Combined hormonal contraception | Strong — substantial, increases with duration, persists after stopping. | Most women, where clinically suitable. Has its own trade-offs. |
| Salpingectomy at other surgery | Good — likely greater than tubal ligation alone. | Women having pelvic surgery whose family is complete. |
| Tubal ligation | Good — meaningful reduction. | Women choosing permanent contraception. |
| Pregnancy and breastfeeding | Good — increases with number and duration. | Context rather than advice; nobody plans this for prevention. |
| Not smoking | Modest, and specific to mucinous subtype. | Everyone, for many other reasons too. |
| Healthy weight | Modest for ovarian; much stronger for endometrial. | Everyone, on its own merits. |
| Supplements, diets, detoxes | None demonstrated. | Nobody, as an ovarian cancer measure. |
| Screening | Not shown to reduce deaths, and not prevention. | Not recommended as protection at any risk level. |
*Absolute risk matters as much as relative reduction. General population lifetime ovarian cancer risk is roughly 1-2%, so a large relative reduction still operates on a small baseline.
Yes, and it is the best-evidenced non-surgical measure available. Combined hormonal contraception substantially reduces ovarian cancer risk, the effect increases with duration of use, and it persists for many years after stopping — the reduction has been observed in BRCA carriers as well as in the general population. It is not a free intervention, however, and should not be presented as one: combined contraception carries its own considerations including a small effect on breast cancer risk, which matters particularly for BRCA carriers, and it is not suitable for everyone. It is worth discussing with a doctor rather than starting for this reason alone.
Nothing with evidence behind it, and it is worth saying plainly. No dietary supplement, superfood, cleanse or detox regimen has been shown to reduce ovarian cancer risk. Some supplements interact with medications and a few carry their own risks at high doses. A generally good diet is worth having for cardiovascular health, weight and a great many other reasons, and maintaining a healthy weight is associated with lower risk of several cancers — but its specific effect on ovarian cancer risk is modest compared with the reproductive factors. Anything sold as ovarian cancer prevention is being sold rather than evidenced.
If you are already having pelvic surgery and your family is complete, it is genuinely worth asking about. Because much high-grade serous ovarian cancer appears to begin in the fallopian tube, surgeons increasingly offer opportunistic salpingectomy — removing the tubes rather than simply tying them — during a hysterectomy or when a woman requests permanent contraception. The ovaries are left in place, so there is no surgical menopause and no hormonal consequence, and it adds little to an operation already being performed. It is not always offered proactively, so it is worth raising explicitly.
No, on two counts. First, screening does not prevent cancer in any case — at best it detects it earlier. Second, and more importantly, ovarian screening with CA-125 and transvaginal ultrasound has not been shown to reduce ovarian cancer deaths, even in high-risk women. There is no ovarian equivalent of cervical or bowel screening, both of which work because they find and remove a precancerous stage. Believing you are protected because you have annual tests is actively worse than knowing you are not, because it can delay acting on symptoms.
Not worried, though it is a recognised risk factor. Never having been pregnant is associated with somewhat higher ovarian cancer risk, because pregnancy interrupts ovulation for extended periods and fewer lifetime ovulations appears to mean lower risk. But the absolute risk remains low — general population lifetime risk is roughly one to two per cent — so a modest relative increase operates on a small baseline. It is context rather than a reason for regret. If it is relevant, combined hormonal contraception offers a similar protective mechanism and is a genuine option to discuss.
Almost, but not completely, and the distinction matters. Removing the ovaries and fallopian tubes reduces ovarian cancer risk by around eighty per cent — not one hundred. The reason is anatomical: the peritoneum, the membrane lining the abdominal cavity, shares an embryological origin with the ovarian surface and cannot be removed, so a small residual risk of primary peritoneal cancer remains for life. In practical terms this means new persistent abdominal symptoms should still be reported rather than dismissed on the grounds that your ovaries are gone.
Yes. The first consultation is free and runs to about 45 minutes, and the most useful part is usually establishing where you actually sit — a woman at population risk and a BRCA1 carrier are in completely different positions, and almost everything on this page applies differently to each. Genetic counselling and BRCA and HRD testing are delivered in-house at CION where family history warrants assessment. Medical oncology is delivered in-house across more than 35 centres; risk-reducing and gynaecologic-oncology surgery is coordinated with specialist partner centres and may be billed there.